Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Mariette

Showing results (21-30 of 593) with videos related to

Pageof 60
Sort By:
Lancet (London, England)|February 1, 2017
Cost-effectiveness of rituximab strategies in rheumatoid arthritisRaphaèle Seror, Xavier Mariette
Nephrologie & Therapeutique|November 19, 2020
[Renal involvement in Sjögren's syndrome]Hélène François, Xavier Mariette
Arthritis & Rheumatology (Hoboken, N.J.)|May 25, 2023
Expert Perspective: Challenges in Sjögren's DiseaseGaetane Nocturne, Xavier Mariette
The Lancet. Oncology|June 5, 2010
RANK and RANKL expression in giant-cell tumour of boneSophie Roux, Xavier Mariette
Lancet (London, England)|May 16, 2003
Low back pain in rural TibetSophie Mariette, Xavier Mariette
Annals of the Rheumatic Diseases|January 5, 2020
Chronic inflammatory arthritis following checkpoint inhibitor therapy for cancer: game changing implicationsLeonard Calabrese, Xavier Mariette
Arthritis & Rheumatology (Hoboken, N.J.)|August 29, 2015
Reply: To PMID 25779552Raphaèle Seror, Xavier Mariette
RMD Open|January 4, 2023
Interferon signature in systemic autoimmune diseases: what does it mean?Gaetane Nocturne, Xavier Mariette
Lancet (London, England)|October 18, 2002
Methotrexate treatment and mortality in rheumatoid arthritisJean Sibilia, Xavier Mariette
Rheumatology (Oxford, England)|December 10, 2019
Management of rheumatic complications of ICI therapy: a rheumatology viewpointJan Leipe, Xavier Mariette
Pageof 60

Showing results (21-30 of 593) with videos related to

Sort By:
Pageof 60
Lancet (London, England)|February 1, 2017
Cost-effectiveness of rituximab strategies in rheumatoid arthritisRaphaèle Seror, Xavier Mariette
Nephrologie & Therapeutique|November 19, 2020
[Renal involvement in Sjögren's syndrome]Hélène François, Xavier Mariette
Arthritis & Rheumatology (Hoboken, N.J.)|May 25, 2023
Expert Perspective: Challenges in Sjögren's DiseaseGaetane Nocturne, Xavier Mariette
The Lancet. Oncology|June 5, 2010
RANK and RANKL expression in giant-cell tumour of boneSophie Roux, Xavier Mariette
Lancet (London, England)|May 16, 2003
Low back pain in rural TibetSophie Mariette, Xavier Mariette
Annals of the Rheumatic Diseases|January 5, 2020
Chronic inflammatory arthritis following checkpoint inhibitor therapy for cancer: game changing implicationsLeonard Calabrese, Xavier Mariette
Arthritis & Rheumatology (Hoboken, N.J.)|August 29, 2015
Reply: To PMID 25779552Raphaèle Seror, Xavier Mariette
RMD Open|January 4, 2023
Interferon signature in systemic autoimmune diseases: what does it mean?Gaetane Nocturne, Xavier Mariette
Lancet (London, England)|October 18, 2002
Methotrexate treatment and mortality in rheumatoid arthritisJean Sibilia, Xavier Mariette
Rheumatology (Oxford, England)|December 10, 2019
Management of rheumatic complications of ICI therapy: a rheumatology viewpointJan Leipe, Xavier Mariette
Pageof 60